Özge ATAY, Suna ASİLSOY, Serdar AL, Gizem ATAKUL, Nevin UZUNER, Özge KANGALLI BOYACIOĞLU, Özkan KARAMAN

Allergic bronchopulmonary Aspergillosis in children

Background/aim: Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in the light of the literature. Materials and methods: Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylül University Child Allergy and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and treatment protocols were analyzed retrospectively. Results: The mean age of patients diagnosed with ABPA was 14.33 ± 1.96. At the time of ABPA diagnosis, the median total IgE level was 1033 IU/mL (1004–6129), and the median AF specific IgE was 10.64 (2.59–49.70) kU/L. Bronchiectasis was detected in HRCT of 5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related complications. Conclusion: Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.Key words: Allergic bronchopulmonary aspergillosis, asthma, cystic fibrosis, child

PDF

___

1. Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60 (8): 1004-1013. doi:10.1111/ j.1398-9995.2005.00887.x
2. Hinson KF, Moon AJ, Plummer NS. Broncho pulmonary aspergillosis; a review and a report of eight new cases. Thorax 1952; 7 (4): 317-333. doi:10.1136/thx.7.4.317
3. Ritz N, Ammann RA, Casaulta AC, Schoeni-Affolter F, Schoeni MH. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. European Journal of Pediatrics 2005; 164: 577- 582. doi:10.1007/s00431-005-1701-4
4. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Annals of Internal Medicine 1977; 86 (4): 405-414. doi:10.7326/0003-4819-86-4- 405
5. Greenberger PA. Allergic bronchopulmonary aspergillosis. The Journal of Allergy and Clinical İmmunology 2002; 110 (5): 685-692. doi:10.1067/mai.2002.130179
6. Agarwal R, Sehgal IS, Dhooria S, Aggarwal AN. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Review of Respiratory Medicine 2016; 10 (12): 1317-1334. doi:10.1080/17476348.2016.1249853
7. Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. The European Respiratory Journal 2006; 27(3): 615-626. doi:10.1183/09031936.06.00074705
8. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: A consensus statement. The Journal of Pediatrics 1998; 132 (4): 589-595. doi:10.1016/s0022-3476(98)70344-0
9. Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta analysis. Clinical and Experimental Allergy 2015; 45 (12): 1765-1778. doi:10.1111/cea.12595 10. Jat KR, Vaidya PC, Mathew JL, Jondhale S, Singh M. Childhood allergic bronchopulmonary aspergillosis. Lung India 2018; 35 (6): 499-507. doi:10.4103/lungindia.lungindia_216_18
11. Singh M, Chauhan A, Paul N, Jaiswal N, Singh S et al. Need to re-look cut-off of Aspergillus-specific IgE levels in children with ABPA. Mycoses 2019; 62 (9): 761-764. doi:10.1111/ myc.12949
12. Agarwal R, Aggarwal AN, Garg M, Saikia B, Chakrabarti A. Cut-off values of serum IgE (total and A. fumigatus -specific) and eosinophil count in differentiating allergic bronchopulmonary aspergillosis from asthma. Mycoses 2014; 57(11): 659-663. doi: 10.1111/myc.12214
13. Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS et al. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India 2015; 32 (1): 3-42. doi:10.4103/0970-2113.154517
14. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest 2006; 130 (2): 442-448. doi:10.1378/chest.130.2.442
15. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy 2013; 43 (8): 850-873. doi:10.1111/cea.12141
16. Nandakumar S, Miller CW, Kumaraguru U. T regulatory cells: an overview and intervention techniques to modulate allergy outcome. Clinical and Molecular Allergy 2009; 7: 5. doi:10.1186/1476-7961-7-5
17. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P et al. Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases 2004; 38 (1): 158. doi:10.1086/376525
18. Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatric Pulmonology 2014; 49 (5): 503-507. doi: 10.1002/ppul.22937
19. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. Journal of Cystic Fibrosis 2009; 8 (4): 253-257. doi: 10.1016/j. jcf.2009.04.008
20. Nove-Josserand R, Grard S, Auzou L, Reix P, Murris-Espin M et al. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatric Pulmonology 2017; 52 (2): 190-197. doi: 10.1002/ppul.23612
21. Agarwal R. What is the current place of azoles in allergic broncho pulmonary aspergillosis and severe asthma with fungal sensitization. Current Respiratory Medicine Reviews 2012; 6 (4): 363–371. doi: 10.1586/ers.12.35
22. Lebrun-Vignes B, Corbrion Archer V, Diquet B, Levron JC, Chosidow O et al. Effect of Itraconazole on the pharmokinetics of prednisolone and methylprednisolone an cortisol secretion in healthy subjects. British Journal of Clinical Pharmacology 2001; 51 (5): 443–450. doi: 10.1046/j.1365-2125.2001.01372.x
23. Aydin Ö, Sözener ZÇ, Soyyigit S, Kendirlinan R, Gençtürk Z et al. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center’s experience with 14 cases. Allergy and Asthma Proceedings 2015; 36 (6): 493-500. doi: 10.2500/ aap.2015.36.3909